Cipla gets USFDA EIR for Bommasandra API facility

Written by Ruchika Sharma Published On 2020-05-10T10:00:57+05:30 | Updated On 10 May 2020 10:01 AM IST

Cipla gets USFDA EIR for Bommasandra API facility

Bangalore: Cipla has announced that it has received Establishment Inspection Report (EIR) from USFDA for its API manufacturing facility in Bommasandra, Bangalore, indicating closure of the inspection.

USFDA had inspected the facility from January 20, 2020, to January 24, 2020.

Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India.

The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.

Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions.

Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries.

ciplausfdaapi

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751